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Abstract 
Despite the significant number of antiviral drugs that are currently available in the clinics of developed countries, 
none of these affect the production stage of HIV-1 replication, more specifically the process of viral gene expression. 
For instance, several early attempts failed to generate inhibitors of the viral Tat protein, the small activator of viral 
transcription from the long terminal repeat (LTR) promoter. A recent study published in Retrovirology by Campos 
et al. presents a new small molecule inhibitor, ABX464, that targets the other small viral protein essential for viral gene 
expression, the Rev protein (Retrovirology 12:30, 2015). Targeting of multiple virus replication steps and silencing the 
generation of new progeny may be of particular value for current attempts to develop novel therapeutic strategies 
that provide a cure or functional cure for HIV-1 infection (Nat Rev Immunol 12: 607–614, 2012). We will briefly review 
some of the unique antiviral properties of ABX464, with the focus on its surprising ability to exhibit a sustained anti-
viral effect in a humanized mouse model. Although ABX464 may remain an important new addition to the anti-HIV 
arsenal, we do present a sobering alternative explanation for the long-lasting reduction in viral load after treatment 
cessation.
© 2015 Berkhout and van der Velden. This article is distributed under the terms of the Creative Commons Attribution 4.0 Interna-
tional License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in 
any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Com-
mons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecom-
mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
In the Retrovirology study [1], ABX464 was shown to 
block HIV-1 replication by preventing the export of 
unspliced viral RNA from the nucleus to the cytoplasm, 
a process that is regulated by the viral Rev protein. No 
direct ABX464-Rev interaction is proposed, but instead 
the drug seems to interact with an important cellular 
RNA regulatory complex. Although this indole drug class 
was originally described as targeting the splicing factor 
SRSF1 [2], ABX464 was found to bind directly to the cap 
binding complex (CBC). CBC controls RNA export and 
RNA splicing and interacts directly with the Rev protein 
[3]. In the new report, ABX464 was proposed to bind 
CBC and to specifically prevent Rev-mediated export 
of viral RNA, without interfering with cap binding or 
export of cellular transcripts [1]. ABX464 is indeed the 
first small molecule drug that (indirectly) targets the Rev 
function, although early gene therapy approaches already 
focused on Rev inhibition [4]. ABX464 is therefore the 
first member of a new drug class that blocks viral gene 
expression in cells that were already infected and in 
which the integrated provirus has already been estab-
lished. The ability to block the production of new viruses 
seems an important asset for attempts to silence viral 
reservoirs.
The new report in Retrovirology adds several impor-
tant new insights on ABX464’s mode of action. First 
and perhaps surprisingly given the proposed binding to 
the cellular CBC regulator, ABX464 does not seem to 
affect other RNA processes in human cells, thus avoiding 
an impact on the physiological state of the cell. Besides 
being non-toxic, ABX464 does not trigger the evolution 
of HIV-1 variants that are resistant to the drug action. 
A likely explanation is that the direct drug target is the 
cellular CBC and not a viral component, consistent with 
previous antiviral strategies [5]. It is therefore also likely 
that this drug will be active against various HIV-1 isolates 
and different subtypes, possibly even HIV-2 if it is simi-
larly dependent on the CBC-Rev axis, but this was not 
tested. On top of this, a remarkable sustained antiviral 
effect was reported in a pre-clinical in vivo model system. 
Thus, ABX464 seems a drug with optimal properties: 
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selective drug action, absence of drug-resistance, and 
a sustained antiviral effect that would be very welcome 
for cure attempts. However, we would like to present an 
alternative explanation for the sustained antiviral effect. 
To do so, we have to discuss in some detail the experi-
mental conditions at which this surprising effect was 
observed.
Profound suppression of the HIV-1 YU2 strain was 
obtained by state of the art combined antiretroviral 
therapy (cART) in the humanized immune system (HIS) 
mouse model, but an immediate rebound of the viral load 
was observed after the treatment was stopped. ABX464 
monotherapy also led to a significant reduction of the 
viral load, but virus suppression was slower and less 
complete than with cART. The perplexing result was 
that this antiviral effect lasted for several weeks after ces-
sation of ABX464 treatment [1]. No such an effect has 
ever been described for other treatments. The explana-
tion provided is that ABX464 prevents virus replication 
in macrophages, thereby blocking the establishment of a 
viral reservoir that will cause the rebound after stopping 
therapy.
There are several reasons why this interpretation is not 
likely. First of all, it seems quite unlikely that macrophages 
form the major cellular component of the HIV-1 reser-
voir [6, 7]. Second, ABX464 could never have blocked all 
reservoir formation as the drug was added only at day 52 
after the experimental infection of the mice. In fact, all 
reservoirs will likely have been established already by that 
time. For instance, a recent macaque study indicated that 
reservoirs are seeded after just 3  days [8]. Although we 
certainly value the power of the HIS mouse model [9], 
this unique in  vivo model remains rather variable and 
complex as each HIS mouse is generated individually 
and critical parameters such as engraftment and source 
of hematopoietic stem cells differ between experiments. 
We like to offer an alternative explanation for these strik-
ing results, also because such a sustained inhibitory effect 
after drug removal has never been described for antivi-
rals, including ABX464, in more simple in vitro settings. 
Because ABX464 does only sub-optimally inhibit YU2 
replication, it could be that most target cells have been 
depleted (by virus replication and/or immune reac-
tions) after 100  days, the moment at which the therapy 
was stopped. The absence of sufficient target cells would 
provide a very simple explanation for the observed lack 
of viral rebound. Although the CCR5-tropic YU2 virus 
has been reported to sustain viral replication for 150–
200 days in HIS mice without a noticeable decline in viral 
load [10, 11], another study [12] demonstrated an almost 
log10 reduction in viral load after 100 days of infection, 
which is in the range of the observed sustained reduc-
tion in viral load upon ABX464 withdrawal and which 
could be explained by a shortage of target cells. In fact, 
some of the additional data in the ABX464 study do sup-
port this alternative scenario. Close inspection of the 
results obtained for individual mice indicates that there 
is a correlation between the viral loads at cessation of 
therapy and the viral loads at the end of the experiment. 
This correlation may be imposed by the number of target 
cells available. One could obviously test this alternative 
explanation in many ways. The authors could for instance 
have refuted this alternative scenario by including an 
untreated YU2-infected group to monitor the CD4+ T 
cell dynamics throughout the experiment and at sacrifice. 
We believe that this commentary is relevant as the origi-
nal study did not entertain any alternative explanations 
for the sustained drug action and the ABX464 antiviral 
was evaluated for the pharmacokinetic properties and 
biological safety in healthy volunteers by the ABIVAX 
biotech company in a Phase 1 study. No serious adverse 
events were scored and no clinically significant abnormal 
result was reported in physical examinations, laboratory 
tests, vital signs and ECG. A Phase 2 study of ABX464 
in patients with HIV was recently initiated. Although we 
would immediately agree that ABX464 remains an inter-
esting drug candidate that could form a welcome addi-
tion to the current classes of antivirals, some caution is 
warranted because the sustained drug action may be an 
artifact of the pre-clinical model system. The search con-
tinues for anti-latency drugs, but one should entertain 
and exclude indirect effects when a magical sustained 
drug action is observed.
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